Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: Modulation of nonneuronal cells

Journal of Pain Research

Volumn 6, Issue , 2013, Pages 239-245

  Keppel Hesselink, Jan M ^a   Kopsky, David J ^b  

^a Institute for Neuropathic Pain   (Netherlands)

^b Institute for Neuropathic Pain   (Netherlands)

Author keywords

Cream; Crps; Endocannabinoid; Ketamine; Mast cells; Palmitoylethanolamide; Sudeck

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; AMITRIPTYLINE; CHLORTALIDONE; DIMETHYL SULFOXIDE; KETAMINE; NORMAST; PALMIDROL; PEAPURE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ABSENCE OF SIDE EFFECTS; AGED; ALLODYNIA; ARTICLE; BURNING SENSATION; CASE REPORT; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CREAM; DRUG DOSE REGIMEN; FALLING; FEMALE; FOOT PAIN; HUMAN; KNEE DISEASE; KNEE INJURY; LIMB SWELLING; LIMITED MOBILITY; MAST CELL DEGRANULATION; PHYSIOTHERAPY; QUALITY OF LIFE; SKIN ATROPHY; SKIN DISCOLORATION; WALKING DIFFICULTY;

EID: 84892861250     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S42417     Document Type: Article

References (69)

1. Moskovitz PA. An overview of CRPS. Pract Pain Manag. 2010;10(1): 47-51.
2. Cossins L, Okell RW, Cameron H, Simpson B, Poole HM, Goebel A. Treatment of complex regional pain syndrome in adults: s systematic review of randomized controlled trials published from Jun 2000 to Feb 2012. Eur J Pain. 2012;17(2):158-173.
3. Tran de QH, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth. 2010; 57(2):149-166.
4. Argoff CE, Albrecht P, Irving G, Rice F. Multimodal analgesia for chronic pain: rationale and future directions. Pain Med. 2009; 10 Suppl 2:S53-S66.
5. Attal N, Bennett DLH, Treede RD. Neuropathic pain update: from basic mechanisms to clinical management. In: Tracey I, editor. Pain 2012 Refresher Courses, 14th World Congress of Pain. Seattle, WA: IASP Press; 2012:85-107.
6. Kopsky DJ, Keppel Hesselink JM. Multimodal stepped care approach involving topical analgesics for severe intractable neuropathic pain in CRPS type 1: a case report. Case Rep Med. 2011;2011:319750.
7. Kopsky DJ, Liebregts R, Keppel Hesselink JM. Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case Rep Med. 2012;2012:471835.
8. Kopsky DJ, Hesselink JM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract. 2012;12(2):148-153.
9. Kopsky DJ, Keppel Hesselink JM. A new combination cream for the treatment of severe neuropathic pain. J Pain Symptom Manage. 2010;39(2):e9-e10.
10. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993;342(8878):1012-1016.
11. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-- D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003; 97(4):1108-1116.
12. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. Pain. 2009;146(1-2):18-25.
13. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010;113(3):713-725.
14. Goebel A, Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev. Epub December 6, 2012.
15. Linnman C, Becerra L, Borsook D. Inflaming the brain: CRPS a model disease to understand neuroimmune interactions in chronic pain. J Neuroimmune Pharmacol. Epub November 29, 2012.
16. Ohara PT, Vit JP, Bhargava A, et al. Gliopathic pain: when satellite glial cells go bad. Neuroscientist. 2009;15(5):450-463.
17. Keppel Hesselink JM. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J. 2012;5:12-23.
18. Levy D, Kainz V, Burstein R, Strassman AM. Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun. 2012;26(2):311-317.
19. Skaper SD, Facci L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3312-3325.
20. Chatterjea D, Wetzel A, Mack M, et al. Mast cell degranulation mediates compound 48/80-induced hyperalgesia in mice. Biochem Biophys Res Commun. 2012;425(2):237-243.
21. Sabsovich I, Guo TZ, Wei T, et al. TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. Pain. 2008;137(3):507-519.
22. Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012;116(4):882-895.
23. Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27(2):101-103.
24. Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11(1):47-51.
25. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. 2006;2006(1):28398.
26. Huygen FJ, Ramdhani N, van ToorenenbergenA, Klein J, Zijlstra FJ. Mast cells are involved in inflammatory reactions during complex regional pain syndrome type 1. Immunology Lett. 2004;91(2-3):147-154.
27. Truini A, Biasiotta A, Di Stefano G, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011;10(8):916-920.
28. Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-442.
29. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121-1130.
30. Esposito E, Cuzzocrea S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev Med Chem. Epub June 13, 2012.
31. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012;26(2):99-104.
32. Skaper SD. Conference report: 1st workshop on palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator. CNS Neurol Disord Drug Targets. 2012;11(3):191.
33. Bacci C, Cassetta G, Emanuele B, Berengo M. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg. 2011;2011:917350.
34. Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med. 2011;102(2):141-147.
35. Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie. 2010;92(6): 724-727.
36. Keppel Hesselink JM. Glia as a new target for neuropathic pain, clinical proof of concept for palmitoylethanolamide, a glia-modulator. Anesth Pain Intensive Care. 2011;15:143-145.
37. Godlewski G, Offertaler L, Wagner JA, Kunos G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediate. 2009;89(3-4):105-111.
38. Hamtiaux L, Hansoulle L, Dauguet N, Muccioli GG, Gallez B, Lambert DM. Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PloS One. 2011;6(10):e26823.
39. Ambrosino P, Soldovieri M, Russo C, Taglialatela M. Activation and desensitization of trpv1 channels in sensory neurons by the peroxisome proliferator-activated receptor α agonist palmitoylethanolamide. Br J Pharmacol. Epub October 19, 2012.
40. Khasabova IA, Xiong Y, Coicou LG, Piomelli D, Seybold V. Peroxisome proliferator-activated receptor alpha mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci. 2012; 32(37):12735-12743.
41. Di Paola R, Impellizzeri D, Mondello P, et al. Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice. Shock. 2012;38(4):356-366.
42. Scuderi C, Valenza M, Stecca C, Esposito G, Carratù MR, Steardo L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferatoractivated receptor-α. J Neuroinflammation. 2012;9:49.
43. Ross RA, Brockie HC, Pertwee RG. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol. 2000;401(2):121-130.
44. Smart D, Gunthorpe MJ, Jerman JC, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol. 2000;129(2):227-230.
45. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002;137(4):413-420.
46. Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ. 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol. 2002;136(3):452-458.
47. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci. 2005; 77(14):1685-1698.
48. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19.
49. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139(3):541-550.
50. Lambert DM, DiPaolo FG, Sonveaux P, et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochimica Biophys Acta. 1999;1440(2-3):266-274.
51. 2 receptors. Br J Pharmacol. 2012;166(4):1474-1489.
52. Sepe N, De Petrocellis L, Montanaro F, Cimino G, Di Marzo V. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim Biophys Acta. 1998;1389(2):101-111.
53. Kuehl FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP. The identification of N-2 (hydroxyethyl)-palmitamide as a naturally occuring anti-inflammatory agent. J Am Chem Soc. 1957;79(19):5577-5578.
54. D'Argenio G, Petrosino S, Gianfrani C, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexatetreated rats. J Mol Med (Berl). 2007;85(5):523-530.
55. Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology. 2005;48(8):1154-1163.
56. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis. 2009;33(1):57-71.
57. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci. 2003; 23(21):7767-7775.
58. Loría F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci. 2008;28(4):633-641.
59. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394(6690): 277-281.
60. Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol. 2001;133(8):1263-1275.
61. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001;419(2-3):191-198.
62. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996;300(3):227-236.
63. Xanthos DN, Gaderer S, Drdla R, et al. Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain. 2011;7:42.
64. Leon A, Buriani A, Dal Toso R, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A. 1994; 91(9):3739-3743.
65. Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? Mol Interv. 2007;7(1):26-41.
66. Michaloudi H, Batzios C, Chiotelli M, Grivas I, Papadopoulos GC. Mast cells populations fluctuate along the spinal dura mater of the developing rat. Brain Res. 2008;1226:8-17.
67. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A. 1995;92(8):3376-3380.
68. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol. 2010;133(1):9-15.
69. Cantarella G, Scollo M, Lempereur L, Saccani-Jotti G, Basile F, Bernardini R. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol. 2011; 82(4):380-388.